Utama › Neurofibrosarkoma › New York
Kajian klinikal Neurofibrosarkoma di New York
6 kajian untuk Neurofibrosarkoma sedang mencari peserta di lokasi di New York.
Bandar di New York
Teks kajian rasmi (Bahasa Inggeris)
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
- New York University Langone Health, New York
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT05732831Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
- Perlmutter Cancer Center at NYU Langone Hospital Long Island, Mineola
- David H Koch, Memorial Sloan Kettering Cancer Center, New York
- New york cancer and blood specialists - Oncology, Port Jefferson Station
- dan 1 lagi
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT05245500SPEARHEAD-3 Pediatric Study
- Memorial Sloan Kettering Kids, New York
Mengambil pesertaFasa 1/2
Umur 2 hingga 21 · Semua jantina · Dikemas kini 11 Ogo 2026 · NCT05642455A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities ), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All protocol activites), New York
- dan 1 lagi
Mengambil pesertaFasa 2
12 Months · Semua jantina · Dikemas kini 6 Mei 2026 · NCT05985161Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
- Memorial Sloan Kettering Cancer Center, New York
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 9 Mac 2026 · NCT03141021A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
- Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center, New York
- dan 1 lagi
Mengambil pesertaFasa 2
Umur 16 ke atas · Semua jantina · Dikemas kini 5 Feb 2026 · NCT04872543Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.